SAKAR HEALTHCARE Q2: ONCOLOGY COMMERCIAL SUPPLIES BEGIN; MANAGEMENT EXPECTS STRONG EXPORT GROWTH

• Commercial Supplies: Commenced domestic and international supplies from its EU GMP-approved, API-integrated oncology manufacturing facility • Global Expansion: Regulatory approvals and growing international partnerships strengthen access to regulated markets • Technology Transfers: Ongoing oncology technology transfer projects support product commercialisation and future revenue growth • API Integration: In-house API manufacturing capabilities expected to improve supply-chain control and operational efficiency • Oncology Portfolio: Expanding product portfolio and regulatory pipeline create additional global growth opportunities • Export Outlook: Management expects growing oncology exports, supported by new approvals and international partnerships • Capacity Utilisation: Higher commercial production volumes expected to improve manufacturing capacity utilisation • Margin Outlook: Improved operating efficiency and API integration could support profitability over the longer term

SAKAR HEALTHCARE LIMITED

← Back to feed